163 related articles for article (PubMed ID: 32324516)
1. Aiming at Ideal Therapeutics-MOPr/DOPr or MOPr-DOPr Heteromertargeting Ligand.
Fujita W
Curr Top Med Chem; 2020; 20(31):2843-2851. PubMed ID: 32324516
[TBL] [Abstract][Full Text] [Related]
2. [MOPr-DOPr heteromer: the meaning and possibility as novel therapeutic target for pain control].
Fujita W
Nihon Yakurigaku Zasshi; 2021; 156(3):134-138. PubMed ID: 33952839
[TBL] [Abstract][Full Text] [Related]
3. LP1 and LP2: Dual-Target MOPr/DOPr Ligands as Drug Candidates for Persistent Pain Relief.
Pasquinucci L; Parenti C; Georgoussi Z; Reina L; Tomarchio E; Turnaturi R
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299443
[TBL] [Abstract][Full Text] [Related]
4. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
[TBL] [Abstract][Full Text] [Related]
6. The Possible Role of MOPr-DOPr Heteromers and Its Regulatory Protein RTP4 at Sensory Neurons in Relation to Pain Perception.
Fujita W
Front Cell Neurosci; 2020; 14():609362. PubMed ID: 33304244
[TBL] [Abstract][Full Text] [Related]
7. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
8. Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.
Kabli N; Martin N; Fan T; Nguyen T; Hasbi A; Balboni G; O'Dowd BF; George SR
Br J Pharmacol; 2010 Nov; 161(5):1122-36. PubMed ID: 20977461
[TBL] [Abstract][Full Text] [Related]
9. Nitro-benzylideneoxymorphone, a bifunctional mu and delta opioid receptor ligand with high mu opioid receptor efficacy.
Olson KM; Devereaux AL; Chatterjee P; Saldaña-Shumaker SL; Shafer A; Plotkin A; Kandasamy R; MacKerell AD; Traynor JR; Cunningham CW
Front Pharmacol; 2023; 14():1230053. PubMed ID: 37469877
[No Abstract] [Full Text] [Related]
10. Alleviating pain with delta opioid receptor agonists: evidence from experimental models.
Berthiaume S; Abdallah K; Blais V; Gendron L
J Neural Transm (Vienna); 2020 Apr; 127(4):661-672. PubMed ID: 32189076
[TBL] [Abstract][Full Text] [Related]
11. Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance.
Mosberg HI; Yeomans L; Anand JP; Porter V; Sobczyk-Kojiro K; Traynor JR; Jutkiewicz EM
J Med Chem; 2014 Apr; 57(7):3148-53. PubMed ID: 24641190
[TBL] [Abstract][Full Text] [Related]
12. Biased Opioid Ligands.
Faouzi A; Varga BR; Majumdar S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32948048
[TBL] [Abstract][Full Text] [Related]
13. Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity.
Gomes I; Fujita W; Gupta A; Saldanha SA; Negri A; Pinello CE; Eberhart C; Roberts E; Filizola M; Hodder P; Devi LA
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):12072-7. PubMed ID: 23818586
[TBL] [Abstract][Full Text] [Related]
14. Bifunctional μ opioid and σ
Zhuang T; Xiong J; Hao S; Du W; Liu Z; Liu B; Zhang G; Chen Y
Eur J Med Chem; 2021 Nov; 223():113658. PubMed ID: 34175542
[TBL] [Abstract][Full Text] [Related]
15. Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment.
Hack SP; Bagley EE; Chieng BC; Christie MJ
J Neurosci; 2005 Mar; 25(12):3192-8. PubMed ID: 15788776
[TBL] [Abstract][Full Text] [Related]
16. Receptor Transporter Protein 4 (RTP4) in the Hypothalamus Is Involved in the Development of Antinociceptive Tolerance to Morphine.
Fujita W; Uchida H; Kawanishi M; Kuroiwa Y; Abe M; Sakimura K
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291680
[TBL] [Abstract][Full Text] [Related]
17. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.
Milan-Lobo L; Enquist J; van Rijn RM; Whistler JL
PLoS One; 2013; 8(3):e58362. PubMed ID: 23554887
[TBL] [Abstract][Full Text] [Related]
18. β-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons.
Rowan MP; Szteyn K; Doyle AP; Gomez R; Henry MA; Jeske NA
Mol Pain; 2014 Aug; 10():50. PubMed ID: 25085415
[TBL] [Abstract][Full Text] [Related]
19. A bifunctional-biased mu-opioid agonist-neuropeptide FF receptor antagonist as analgesic with improved acute and chronic side effects.
Drieu la Rochelle A; Guillemyn K; Dumitrascuta M; Martin C; Utard V; Quillet R; Schneider S; Daubeuf F; Willemse T; Mampuys P; Maes BUW; Frossard N; Bihel F; Spetea M; Simonin F; Ballet S
Pain; 2018 Sep; 159(9):1705-1718. PubMed ID: 29708942
[TBL] [Abstract][Full Text] [Related]
20. Heteromer Induction: An Approach to Unique Pharmacology?
Portoghese PS; Akgün E; Lunzer MM
ACS Chem Neurosci; 2017 Mar; 8(3):426-428. PubMed ID: 28139906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
